FDA Approves Entrectinib for Pediatric Solid Tumors

News
Article

Results from the phase 1/2 STARTRK-NG and phase 2 TAPISTRY trials led to the approval of entrectinib for patients who are 1 month or older with solid tumors.

The approval is based on 2 multicenter, single-arm trials: the phase 1/2 STARTRK-NG study (NCT02650401), and the phase 2 TAPISTRY study (NCT04589845).

The approval is based on 2 multicenter, single-arm trials: the phase 1/2 STARTRK-NG study (NCT02650401), and the phase 2 TAPISTRY study (NCT04589845).

Entrectinib (Rozlytrek) has been given accelerated approval by the FDA for pediatric patients who are 1 month or older with solid tumors, according to a press release from the organization.1

The indication includes patients with NTRK gene fusions without a known acquired resistance mutation, metastatic disease or where surgical resection is likely to result in severe morbidity, and progression following treatment or those who have no satisfactory standard therapy.

The approval is based on 2 multicenter, single-arm trials: the phase 1/2 STARTRK-NG study (NCT02650401), and the phase 2 TAPISTRY study (NCT04589845). A total of 33 patients were enrolled between both trials with dosing based on body surface area of 20 mg to 600 mg given orally or through an enteral feeding tube once daily.

Investigators aimed to assess the overall response rate (ORR) as analyzed by blinded independent central review via RECIST 1.1 criteria for extracranial tumors and the Response Assessment in Neuro-Oncology (RANO) for primary central nervous system (CNS) tumors. The ORR was 70% (95% CI, 51%-84%), and the median duration of response was 25.4 months (95% CI, 14.3-not evaluable).

Patients were most commonly diagnosed with primary CNS tumors and infantile fibrosarcoma. The most common adverse effects included pyrexia, constipation, increased weight, vomiting, diarrhea, and nausea.

For patients who are older than 1 month and 6 months or younger, the recommend dose is 250 mg/m2 orally once daily. For those older than 6 months, the dose is based on body surface area and can be given up to 600 mg once daily.

In August 2019, entrectinib was granted accelerated approval for patients 12 years and older based on the same indication as well as patients with non–small cell lung cancer who have ROS1-positive tumors.2

References

  1. FDA expands pediatric indication for entrectinib and approves new pellet formulation. News release. FDA. October 20, 2023. Accessed October 20, 2023. https://bit.ly/46Dpqtv
  2. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. News release. FDA. August 15, 2019. Accessed October 20, 2023. https://bit.ly/46PA8Nc
Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.

Data Highlight Pervasive Racial/Ethnic Disparities in Health Care

May 3rd 2024
Article

Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Elderly Cancer Populations Have Inconsistent Symptom Burden/Clusters

April 26th 2024
Article

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Saruparib Shows Favorable Activity, Safety in Mutant Advanced Solid Tumors

April 8th 2024
Article

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.